The DOI matches its Crossref record; 368 of the 371 references it cites were found in a registry or an index.
EASL Clinical Practice Guidelines: Drug-induced liver injury
Abstract
Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drug-induced liver injury (DILI) is an uncommon adverse reaction to drugs, and other chemicals, including herbal and dietary supplements (HDS).”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“The vast majority of cases of DILI occur at therapeutic doses in a small proportion of individuals exposed to the drug, representing an idiosyncratic reaction, and therefore unpredictable based on the drug's mechanism of action and related to the uniqueness of the individual [1,2].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“In pediatric medicine, DILI is a rare clinical situation. However, it has high morbidity and mortality, and it is one of the most common causes of acute liver failure. Furthermore, its diagnosis is clinically challenging due to its low incidence and phenotypic variability [6,7,8].”
From Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM (2023) · cites this paper as [7]
In the citing paper
“The lack of a reliable diagnostic biomarker and evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“The lack of reliable diagnostic biomarkers and an evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.2,25–27”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“However, drug rechallenge in DILI cases is potentially dangerous2,75 and is associated with risk of death or requirement for liver transplant.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“High TBil and ALP levels in the second month after an acute DILI episode and the biochemical nonresolution-6 model may help predict the risk of chronic injury and delayed recovery [26,72].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Its potential value in confirming or excluding hepatocellular injury in cases of elevated ALT levels from a suspected extrahepatic origin (e.g., muscle) has been evaluated [26,175].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Ekor, M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00177 · Cited by 3,919
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Acetaminophen‐induced acute liver failure
Larson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., REISCH, J. S., Schiødt, F. V., Ostapowicz, G., Shakil, A. O., et al. (2005) · Hepatology · doi:10.1002/hep.20948 · Cited by 1,934
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Research works printed but not linked: 5
- Nicoletti, 2017, Genome-wide association study (GWAS) to identify genetic risk factors that increase susceptibility to antituberculosis drug-induced liver injury (ATDILI) [Abstract], Hepatology, 66, A-25
- Lim, 2008, Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review, Neurol Asia, 13, 15
- US Food & Drug Administration, 2017, Drugs
- Sanjuan-Jimenez, 2017, Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury [abstract], Hepatology, 66, 423A
- Fernández-Castañer, 2008, An analysis of the causes, characteristics, and consequences of reexposure to a drug or compound responsible for a hepatotoxicity event, Rev Esp Enfermedades Dig, 100, 278
Cited by
Sorted by citations
COVID-19: Abnormal liver function tests
Cai, Q., Huang, D., Yu, H., Zhu, Z., Zhang, X., Su, Y., Li, Z., Zhou, G., Gou, J., Qu, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.006 · Cited by 1,096
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citationKarlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01701-3 · Cited by 652
Self-citationCOVID‐19 in a designated infectious diseases hospital outside Hubei Province, China
Cai, Q., Huang, D., Ou, P., Yu, H., Zhu, Z., Zhang, X., Su, Y., Ma, Z., Zhang, Y., Li, Z., et al. (2020) · Allergy · doi:10.1111/all.14309 · Cited by 507
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 416
Dissecting the Crosstalk Between Nrf2 and NF-κB Response Pathways in Drug-Induced Toxicity
Gao, W., Guo, L., Yang, Y., Wang, Y., Xia, S., Gong, H., Zhang, B., & Yan, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.809952 · Cited by 358
Trebicka, J., Fernández, J., Papp, M., Caraceni, P., Laleman, W., Gambino, C. G., Giovo, I., Uschner, F. E., Jansen, C., Jiménez, C., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.019 · Cited by 316
Drug induced liver injury: an update
García‐Cortés, M., Robles‐Díaz, M., Stephens, C. M., Ortega‐Alonso, A., Lucena, M. I., & Andrade, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02885-1 · Cited by 306
Self-citationSuperoxide Dismutase Administration: A Review of Proposed Human Uses
Rosa, A. C., Corsi, D., Cavi, N., Bruni, N., & Dosio, F. (2021) · Molecules · doi:10.3390/molecules26071844 · Cited by 297
The microbiota in cirrhosis and its role in hepatic decompensation
Trebicka, J., Macnaughtan, J., Schnabl, B., Shawcross, D. L., & Bajaj, J. S. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.013 · Cited by 283
Hutchison, A. L., Tavaglione, F., Romeo, S., & Charlton, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.030 · Cited by 250
Paz, M. V., Morán, L., López‐Alcántara, N., Freixo, C., Andrade, R. J., Lucena, M. I., & Cubero, F. J. (2021) · Antioxidants · doi:10.3390/antiox10030390 · Cited by 234
Self-citationDrug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management
Björnsson, H., & Björnsson, E. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.10.035 · Cited by 212
Self-citationChinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
Sun, H., Zhou, J., Wang, Z., Liu, X., Xie, Q. M., Jia, W., Zhao, M. D., Bi, X., Gong, L., Bai, X., et al. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-328 · Cited by 210
A human liver organoid screening platform for DILI risk prediction
Zhang, C. J., Meyer, S. R., O’Meara, M. J., Huang, S., Capeling, M. M., Ferrer-Torres, D., Childs, C. J., Spence, J. R., Fontana, R. J., & Sexton, J. Z. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.019 · Cited by 203
The exposome and liver disease - how environmental factors affect liver health
Barouki, R., Samson, M., Blanc, É., Colombo, M. G., Zucman‐Rossi, J., Lazaridis, K. N., Miller, G. W., & Coumoul, X. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.034 · Cited by 189
Niu, B., Lei, X., Xu, Q., Ju, Y., Xu, D., Mao, L., Li, J., Zheng, Y., Sun, N., Zhang, X., et al. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09624-x · Cited by 186
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Self-citationLiver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
Martin, E. D., Michot, J., Rosmorduc, O., Guettier, C., & Samuel, D. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100170 · Cited by 183
Mostafa, A., Kandeil, A., Elshaier, Y. A. M. M., Kutkat, O., Moatasim, Y., Rashad, A. A., Shehata, M., Gomaa, M. R., Mahrous, N., Mahmoud, S. H., et al. (2020) · Pharmaceuticals · doi:10.3390/ph13120443 · Cited by 175
Granito, A., Muratori, L., Lalanne, C., Quarneti, C., Ferri, S., Guidi, M., Lenzi, M., & Muratori, P. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i22.2994 · Cited by 175
Incidence and risk factors of drug‐induced liver injury
Li, X., Tang, J., & Mao, Y. (2022) · Liver International · doi:10.1111/liv.15262 · Cited by 158
EASL Clinical Practice Guidelines on the management of autoimmune hepatitis
Dalekos, G., Gatselis, N., Drenth, J. P. H., Heneghan, M., Jørgensen, M., Lohse, A. W., Londoño, M., Muratori, L., Papp, M., Samyn, M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.017 · Cited by 175
Drug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.033 · Cited by 166
Self-citationA revised electronic version of RUCAM for the diagnosis of DILI
Hayashi, P. H., Lucena, M. I., Fontana, R. J., Bjornsson, E. S., Aithal, G. P., Barnhart, H., Gonzalez‐Jimenez, A., Yang, Q., Gu, J., Andrade, R. J., et al. (2022) · Hepatology · doi:10.1002/hep.32327 · Cited by 160
Self-citationComprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry
Stephens, C., Robles-Diaz, M., Medina-Caliz, I., Garcia-Cortes, M., Ortega-Alonso, A., Sanabria-Cabrera, J., Gonzalez-Jimenez, A., Alvarez-Alvarez, I., Slim, M., Jimenez-Perez, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.029 · Cited by 148
Self-citationMolecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives
Fu, S., Wu, D., Jiang, W., Li, J., Jiang, L., Jia, C., & Zhou, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01667 · Cited by 148
Oxidative Stress–Induced Liver Damage and Remodeling of the Liver Vasculature
Banerjee, P., Gaddam, N., Chandler, V., & Chakraborty, S. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.06.002 · Cited by 147
EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy
Williamson, C., Nana, M., Poon, L. C., Kupčinskas, L., Painter, R. C., Taliani, G., Heneghan, M. A., Marschall, H., & Beuers, U. H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.006 · Cited by 145
Wong, G. L., Wong, V. W., Thompson, A. J. V., Jia, J., Hou, J., Lesmana, C. R. A., Susilo, A., Tanaka, Y., Chan, W., Gane, E. J., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30190-4 · Cited by 140
Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy
Subramaniyan, V., Chakravarthi, S., Jegasothy, R., Wu, Y. S., Fuloria, N. K., Fuloria, S., Hazarika, I., & Das, A. (2021) · Toxicology Reports · doi:10.1016/j.toxrep.2021.02.010 · Cited by 138
Aghemo, A., Alekseeva, O. P., Angelico, F., Бакулин, И. Г., Бакулина, Н. В., Bordin, D. S., Bueverov, A. O., Drapkina, O. M., Gillessen, A., Kagarmanova, E. M., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2069854 · Cited by 138
Roussel uclaf causality assessment method for drug-induced liver injury: Present and future
Danan, G., & Teschke, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00853 · Cited by 111
Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults
Stättermayer, A. F., Halilbasic, E., Wrba, F., Ferenci, P., & Trauner, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.036 · Cited by 120
Muhovic, D. F., Bojovic, J. B., Bulatović, A., Vukčević, B., Ratković, M., Lazović, R., & Smolović, B. (2020) · Liver International · doi:10.1111/liv.14516 · Cited by 119
Immune checkpoint inhibitor-related hepatotoxicity: A review
Remash, D., Prince, D. S., McKenzie, C. A., Strasser, S. I., Kao, S., & Liu, K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5376 · Cited by 118
Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review
Li, M., Luo, Q., Tao, Y., Sun, X., & Liu, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.806249 · Cited by 116
Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation
Meunier, L., & Larrey, D. G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01482 · Cited by 112
Self-citationAcetaminophen-induced liver injury: Molecular mechanism and treatments from natural products
Liao, J., Lu, Q., Li, Z., Li, J., Zhao, Q., & Li, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1122632 · Cited by 111
Herb-induced liver injury: Systematic review and meta-analysis
Ballotin, V. R., Bigarella, L. G., Brandão, A. B. D. M., Balbinot, R. Â., Balbinot, S. S., & Soldera, J. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i20.5490 · Cited by 110
Intestinal Dysbiosis Amplifies Acetaminophen-Induced Acute Liver Injury
Schneider, K. M., Elfers, C., Ghallab, A., Schneider, C. V., Galvez, E. J. C., Mohs, A., Gui, W., Candels, L. S., Wirtz, T. H., Zuehlke, S., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.11.002 · Cited by 108
ResNet18DNN: prediction approach of drug-induced liver injury by deep neural network with ResNet18
Zhao, C. X., Jiang, Y., Zhang, X., Zheng, R., Qiu, R., Sun, Y., Zhao, C. X., & Shang, H.-C. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab503 · Cited by 108
Pi, B., Wang, J., Tong, Y., Yang, Q., Lv, F., & Yu, Y. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002280 · Cited by 105
Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same
Olry, A., Meunier, L., Delire, B., Larrey, D. G., Horsmans, Y., & Louët, H. L. (2020) · Drug Safety · doi:10.1007/s40264-020-00954-z · Cited by 102
Self-citationClinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort
Hountondji, L., Matos, C. F. D., Lebossé, F., Quantin, X., Lesage, C., Palassin, P., Rivet, V., Faure, S., Pageaux, G., Assénat, E., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100719 · Cited by 103
Self-citationApproach to the patient with acute severe autoimmune hepatitis
Rahim, M. N., Miquel, R., & Heneghan, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100149 · Cited by 95
Chemotherapy-associated steatohepatitis
Meunier, L., & Larrey, D. G. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2019.11.012 · Cited by 94
Self-citationMicrobiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury
Rodriguez, C., Taminiau, B., García-García, A., Cueto‐Sánchez, A., Robles‐Díaz, M., Ortega‐Alonso, A., Martín‐Reyes, F., Daube, G., Sanabria‐Cabrera, J., Pérez, M. J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106348 · Cited by 94
Self-citationDrug-induced liver injury in older people
Lucena, M. I., Sanabria, J., García-Cortes, M., Stephens, C., & Andrade, R. J. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30006-6 · Cited by 77
Self-citationDrug‐induced peripheral oedema: An aetiology‐based review
Largeau, B., Cracowski, J., Lengellé, C., Sautenet, B., & Jonville‐Béra, A. ‐. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14752 · Cited by 89
Moloi, T. P., Ziqubu, K., Mazibuko-Mbeje, S. E., Mabaso, N. H., & Ndlovu, Z. (2024) · Toxicology · doi:10.1016/j.tox.2024.153983 · Cited by 89
Immune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
Self-citationPonziani, F. R., Zompo, F. D., Nesci, A., Santopaolo, F., Ianiro, G., Pompili, M., Gasbarrini, A., & “Gemelli against COVID‐19” group (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15996 · Cited by 85
Polygenic architecture informs potential vulnerability to drug-induced liver injury
Koido, M., Kawakami, E., Fukumura, J., Noguchi, Y., Ohori, M., Nio, Y., Nicoletti, P., Aithal, G. P., Daly, A. K., Watkins, P. B., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1023-0 · Cited by 84
Self-citationShi, S., Wang, X., van der Laan, L. J. W., Pan, Q., & Verstegen, M. M. A. (2021) · Transplantation · doi:10.1097/tp.0000000000003691 · Cited by 85
Liu, Z., Zhu, Y., Xie, H., & Zou, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077468 · Cited by 88
Lombardi, N., Crescioli, G., Maggini, V., Ippoliti, I., Menniti‐Ippolito, F., Gallo, E. R., Brilli, V., Lanzi, C., Mannaioni, G., Firenzuoli, F., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14460 · Cited by 85
Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China
Zhu, L., Zhang, C., Li, D.-P., Chen, H., Ma, J., Gao, H., Ye, Y., Wang, J.-Y., Fu, P. P., & Lin, G. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00553-9 · Cited by 81
Autoimmune hepatitis following COVID-19 vaccination: True causality or mere association?
Tan, C. K., Wong, Y. J., Wang, L. M., Ang, T. L., & Kumar, R. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.009 · Cited by 81
Drug‐Induced Liver Injury in GI Practice
Sandhu, N., & Navarro, V. J. (2020) · Hepatology Communications · doi:10.1002/hep4.1503 · Cited by 78
Hao, S.-R., Zhang, S.-Y., Lian, J., Jin, X., Ye, C.-Y., Cai, H. Q., Zhang, X., Hu, J.-H., Zheng, L., Zhang, Y.-M., et al. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000717 · Cited by 78
Gustot, T., Stadlbauer, V., Laleman, W., Alessandria, C., & Thursz, M. R. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.005 · Cited by 76
Mizuno, K., Ito, T., Ishigami, M., Ishizu, Y., Kuzuya, T., Honda, T., Kawashima, H., Inukai, Y., Toyoda, H., Yokota, K., et al. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01677-9 · Cited by 73
Management of hepatotoxicity of chemotherapy and targeted agents.
Mudd, T. W., & Guddati, A. K. (2021) · PubMed · Cited by 89
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Self-citationBjörnsson, E. S., Stephens, C., Atallah, E., Robles‐Diaz, M., Alvarez‐Alvarez, I., Gerbes, A., Weber, S., Stirnimann, G., Kullak‐Ublick, G., Cortez‐Pinto, H., et al. (2023) · Liver International · doi:10.1111/liv.15378 · Cited by 69
Self-citationHarnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury
Liu, M., Huang, Q., Zhu, Y., Chen, L., Li, Y., Gong, Z., & Ai, K. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100215 · Cited by 70
Mitochondrial Dysfunction and Chronic Liver Disease
Zhang, C., Zhao, Y., Yu, M., Qin, J., Ye, B., & Wang, Q. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44070218 · Cited by 68
Bischoff, S. C., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Eshraghian, A., Kani, H. T., Khannoussi, W., Lacaze, L., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.07.003 · Cited by 70
The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury
Fontana, R. J., Bjornsson, E. S., Reddy, K. R., & Andrade, R. J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.12.040 · Cited by 69
Self-citationGuideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)
Brennan, P., Cartlidge, P., Manship, T. A., & Dillon, J. F. (2021) · Frontline Gastroenterology · doi:10.1136/flgastro-2021-101886 · Cited by 66
Lee, B. P., Witkiewitz, K. A., Mellinger, J. L., Anania, F. A., Bataller, R. A., Cotter, T. G., Curtis, B. L., Dasarathy, S., DeMartini, K. S., Diamond, I., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00936-x · Cited by 65
Biologic and checkpoint inhibitor‐induced liver injury: a systematic literature review
Shah, P., Sundaram, V., & Björnsson, E. (2020) · Hepatology Communications · doi:10.1002/hep4.1465 · Cited by 64
Vasques, F., Cavazza, A., & Bernal, W. (2022) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000923 · Cited by 64
Systematic review: ibuprofen‐induced liver injury
Zoubek, M. E., Lucena, M. I., Andrade, R. J., & Stephens, C. M. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15645 · Cited by 64
Self-citationLodato, F., Larocca, A., D’Errico, A., & Cennamo, V. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.005 · Cited by 63
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
Clinical standards for the management of adverse effects during treatment for TB
Singh, K. P., Carvalho, A. C., Centis, R., D´Ambrosio, L., Migliori, G. B., Mpagama, S. G., Nguyen, B. C., Aarnoutse, R. E., Aleksa, A., van Altena, R., et al. (2023) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.23.0078 · Cited by 62
Niu, H., Sanabria-Cabrera, J., Alvarez-Alvarez, I., Robles-Diaz, M., Stankevičiūtė, S., Aithal, G. P., Björnsson, E. S., Andrade, R. J., & Lucena, M. I. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105404 · Cited by 58
Self-citationBischoff, S. C., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Eshraghian, A., Kani, H. T., Khannoussi, W., Lacaze, L., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12280 · Cited by 62
Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review
Benić, M. S., Nežić, L., Vujić‐Aleksić, V., & Mititelu-Tarțău, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.785790 · Cited by 59
Clinical management of patients with drug‐induced liver injury (DILI)
Bjornsson, E. S. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12113 · Cited by 58
Characteristics of peripheral blood Gamma-glutamyl transferase in different liver diseases
Xing, M., Gao, M., Li, J., Han, P., Mei, L., & Zhao, L. (2022) · Medicine · doi:10.1097/md.0000000000028443 · Cited by 58
Sanabria‐Cabrera, J., Tabbai, S., Niu, H., Álvarez‐Álvarez, I., Licata, A., Bjornsson, E. S., Andrade, R. J., & Lucena, M. I. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876868 · Cited by 58
Self-citationDiagnostic and prognostic assessment of suspected drug‐induced liver injury in clinical practice
Andrade, R. J., & Robles‐Díaz, M. (2019) · Liver International · doi:10.1111/liv.14271 · Cited by 58
Self-citationEASL Clinical Practice Guidelines on vascular diseases of the liver
Rautou, P., Moga, L., Hernández–Gea, V., Walter, A., Murad, S. D., García‐Pagán, J. C., Guido, M., McLin, V. A., Tripathi, D., & Vilgrain, V. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.001 · Cited by 57
Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID‐19
Yip, T. C., Wong, V. W., Lui, G. C.-Y., Chow, V. C., Tse, Y., Hui, V. W., Liang, L. Y., Chan, H. L., Hui, D. S. C., & Wong, G. L. (2021) · Hepatology · doi:10.1002/hep.31890 · Cited by 56
Robles‐Díaz, M., Nežić, L., Vujić‐Aleksić, V., & Bjornsson, E. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.744488 · Cited by 56
Bessone, F., Hernández, N., Tagle, M., Arrese, M. A., Paraná, R., Méndez‐Sánchez, N., Ridruejo, E., Mendizábal, M., Dagher, L., Contreras, F., et al. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100321 · Cited by 57
Long-term sequelae of drug-induced liver injury
Bjornsson, E. S., & Andrade, R. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.011 · Cited by 54
Self-citationNayagam, J. S., Williamson, C., Joshi, D., & Thompson, R. J. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16118 · Cited by 53
Gasmi, B., & Kleiner, D. E. (2019) · Clinics in Liver Disease · doi:10.1016/j.cld.2019.09.004 · Cited by 53
In Vitro Models for Studying Chronic Drug-Induced Liver Injury
Donato, M. T., Ferrer, G. G., & Tolosa, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911428 · Cited by 52
Biolato, M., Bianco, A. D., Lucchini, M., Gasbarrini, A., Massimiliano Mirabella, A., & Grieco, A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00842-9 · Cited by 52
Wong, C. K. H., Mak, L., Au, I. C. H., Lai, F. T. T., Li, X., Wan, E. Y. F., Chui, C. S. L., Chan, E. W., Cheng, W. Y., Cheng, F. W. T., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.032 · Cited by 51
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Martin, E. D., Fulgenzi, C. A. M., Celsa, C., Laurent-Bellue, A., Torkpour, A., Lombardi, P., D’Alessio, A., & Pinato, D. J. (2024) · Gut · doi:10.1136/gutjnl-2024-332125 · Cited by 51
Metamizole: An underrated agent causing severe idiosyncratic drug‐induced liver injury
Sebode, M., Reike‐Kunze, M., Weidemann, S. A., Zenouzi, R., Hartl, J., Peiseler, M., Liwinski, T., Schulz, L., Weiler‐Normann, C., Sterneck, M. R., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14254 · Cited by 50
Rana, P., Aleo, M. D., Wen, X., & Kogut, S. J. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.028 · Cited by 50
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination
Codoni, G., Kirchner, T., Engel, B., Villamil, A. M., Efe, C., Stättermayer, A. F., Weltzsch, J. P., Sebode, M., Bernsmeier, C., Lleo, A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100605 · Cited by 37
Self-citation
Metadata
- Authors
- Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 70
- Issue
- 6
- Pages
- 1222-1261
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2924328881
- Semantic Scholar
- 6d774d1c570eef200451a1e8a8f5655c367a4eaf
- Cited by
- 1,276
- References
- 371
- Citations by year
- 2026: 243 · 2025: 211 · 2024: 175 · 2023: 159 · 2022: 158 · 2021: 184 · 2020: 117 · 2019: 27
- FWCI
- 78.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Cooperation in Science & Technology
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- drug-induced liver injury, idiosyncratic drug-induced liver injury, hepatotoxicity, acute liver failure, risk factors, diagnosis, risk minimization
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Histocompatibility Testing, Humans, Liver Neoplasms, Male, Middle Aged, Mitochondria, Risk Factors, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
